Ticker Details
Agios Pharmaceuticals, Inc. Agios Pharmaceuticals Inc is a biopharmaceutical company which focuses on developing treatments geared towards cancer and rare genetic disorders of metabolism. It also emphasizes on developing potentially transformative small-molecule medicines.
IPO Date:	July 24, 2013
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$1.71B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$1.20 | 2.53%
Avg Daily Range (30 D):	$0.51 | 1.82%
Avg Daily Range (90 D):	$0.60 | 1.92%

Institutional Daily Volume
Avg Daily Volume:	.55M
Avg Daily Volume (30 D):	.73M
Avg Daily Volume (90 D):	1.14M

Trade Size
Avg Trade Size (Sh.):	74
Avg Trade Size (Sh.) (30 D):	55
Avg Trade Size (Sh.) (90 D):	68

Institutional Trades
Total Institutional Trades:	6,167
Avg Institutional Trade:	$2.34M
Avg Institutional Trade (30 D):	$2.51M
Avg Institutional Trade (90 D):	$2.38M
Avg Institutional Trade Volume:	.06M
Avg Institutional Trades (Per Day):	2

Market Closing Trades
Avg Closing Trade:	$3.24M
Avg Closing Trade (30 D):	$3.72M
Avg Closing Trade (90 D):	$4.42M
Avg Closing Volume:	80K

News

Jan 26, 2026 @ 12:00 PM Agios to Host Fourth Quarter and Full Year 2025 Fi... Source: Na

Dec 24, 2025 @ 5:03 PM Here's Why Shares in Agios Pharmaceuticals Popped ... Source: Lee Samaha

Dec 24, 2025 @ 12:45 AM U.S. FDA Approves Agios’ AQVESME™ (mi... Source: Agios Pharmaceuticals, Inc.

Dec 3, 2025 @ 6:00 PM Sickle Cell Disease Market is Predicted to Exhibit... Source: Delveinsight

Nov 19, 2025 @ 6:33 PM Why Shares in Agios Pharmaceuticals Got Crushed To... Source: Lee Samaha

Financials
	TTM	Q4 2025	FY 2025
Basic EPS	$-7.12	$-1.85	$-7.12
Diluted EPS	$-7.12	$-1.85	$-7.12
Revenue	$54.03M	$19.97M	$54.03M
Gross Profit	$47.68M	$18.09M	$47.68M
Net Income / Loss	$-412.78M	$-108.04M	$-412.78M
Operating Income / Loss	$-472.13M	$-121.58M	$-472.13M
Cost of Revenue	$6.35M	$1.88M	$6.35M
Net Cash Flow	$12.88M	$-3.58M	$12.88M
PE Ratio